Hansa Biopharma AB (Hansa Biopharma AB) Gross Margin % : 67.57% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Hansa Biopharma AB Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Hansa Biopharma AB's Gross Profit for the three months ended in Mar. 2024 was $3.63 Mil. Hansa Biopharma AB's Revenue for the three months ended in Mar. 2024 was $5.38 Mil. Therefore, Hansa Biopharma AB's Gross Margin % for the quarter that ended in Mar. 2024 was 67.57%.

Warning Sign:

Hansa Biopharma AB gross margin has been in long-term decline. The average rate of decline per year is -5.5%.

The historical rank and industry rank for Hansa Biopharma AB's Gross Margin % or its related term are showing as below:

HNSBF' s Gross Margin % Range Over the Past 10 Years
Min: 52.91 Med: 75.1 Max: 93.58
Current: 56.8

During the past 13 years, the highest Gross Margin % of Hansa Biopharma AB was 93.58%. The lowest was 52.91%. And the median was 75.10%.

HNSBF's Gross Margin % is ranked worse than
53.12% of 738 companies
in the Biotechnology industry
Industry Median: 59.44 vs HNSBF: 56.80

Hansa Biopharma AB had a gross margin of 67.57% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Hansa Biopharma AB was -5.50% per year.

Hansa Biopharma AB Gross Margin % Historical Data

The historical data trend for Hansa Biopharma AB's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Gross Margin % Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

74.23

83.68

54.47

75.10

52.91

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial															60.16	48.96	27.09	64.03	67.57

Competitive Comparison of Hansa Biopharma AB's Gross Margin %

For the Biotechnology subindustry, Hansa Biopharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Gross Margin % falls into.

Hansa Biopharma AB Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Hansa Biopharma AB's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	6.9	/	13.073
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(13.073 - 6.156)	/	13.073
	=	52.91 %

Hansa Biopharma AB's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	3.6	/	5.377
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(5.377 - 1.744)	/	5.377
	=	67.57 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Hansa Biopharma AB (OTCPK:HNSBF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hansa Biopharma AB had a gross margin of 67.57% for the quarter that ended in Mar. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Hansa Biopharma AB Gross Margin % Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (Hansa Biopharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OTCPK:HNSBF) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

HNSA:Sweden 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.